Rb-82 Radiotracer Grows at Rapid Rate

June 14, 2010 – A radio tracer is quickly gaining popularity among cardiologists in the United States.

Bracco Diagnostics Inc. recently announced that its CardioGen-82 (rubidium Rb 82 generator) is achieving unprecedented growth in the United States. Over the past five years, CardioGen-82 has experienced double-digit year-over-year growth, with a marked increase recorded in the past nine months. [1] Cardiologists, radiologists, and nuclear medicine physicians will perform an estimated 145,000 positron emission tomography (PET) myocardial perfusion imaging (MPI) procedures in 2010 using CardioGen-82. [2]

Several key factors have contributed to this growth, including increasing momentum for the modality of cardiac PET, publication of key clinical data, and improvements in PET hardware/software technology and accessibility.

CardioGen-82 is the only FDA-approved generator-based PET MPI tracer reimbursed for the evaluation of coronary artery disease (CAD). [3]

As the significant shortage of SPECT (single photon emission computed tomography) MPI tracers made using Mo-99 continues, many nuclear cardiology labs have adopted cardiac PET with CardioGen-82 as a standard of patient care. With the closing of both National Research Universal’s Chalk River reactor in Canada – the source of more than half the world’s supply of Mo-99 – and the Petten reactor in the Netherlands, and no short-term fix in sight, health care providers face significant pressure to find alternate ways to meet the needs of their CAD patients beyond the standard practices they have typically and previously employed.

Since PET MPI procedures can be performed in as little as 30 minutes or less, there are great efficiencies offered by this technique. [4, 5] “The reduced scan time compared with SPECT helps to improve patient satisfaction,” says referring cardiologist Kyle Richards, M.D. of Pioneer Valley Cardiology in Springfield, Mass.

Moreover, PET MPI offers greater interpretive certainty for imagers, according to a publication in the Journal of Nuclear Cardiology by Tim Bateman, M.D. of Cardiovascular Consultants in Kansas City, Mo., and his colleagues: “A significantly lower percent (81 percent) of SPECT scans were able to be interpreted as definitely normal or abnormal compared with 96 percent of PET images (p=.0008).” [5]

For more information: www.cardiogen.com.

References:

[1] Bracco Sales Data on file

[2] Bio-Tech Systems, Inc. PET Market Report July 2009

[3] Medicare National Coverage Determination 220.6.1

[4] Dorbala S., Hachamovitch R., Curillova Z., et al. “Incremental Prognostic Value of Gated Rb-82 Positron Emission Tomography Myocardial Perfusion Imaging Over Clinical Variables and Rest LVEF.” Journal of the American College of Cardiology. 2009;2;846-854.

[5] Bateman T.M., Heller G.V., McGhie A.l., et al. “Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: comparison with ECG-gated Tc-99m sestamibi SPECT.” Journal of Nuclear Cardiology. 2006;13:24-33.

Related Content

Feature | Nuclear Imaging

The "Nuclear Medicine Market Size, Share & Trends Analysis Report by Product (Diagnostics (SPECT, PET)), Therapeutics ...

Time May 26, 2022
arrow
News | Proton Therapy

May 25, 2022 — B dot Medical Inc. and Research Center for Nuclear Physics, Osaka University (RCNP) have conducted a ...

Time May 25, 2022
arrow
News | Contrast Media

May 19 2022 — Recent disruptions in a pharmaceutical supply chain have impacted the global availability of GE Healthcare ...

Time May 19, 2022
arrow
News | Contrast Media

May 18, 2022 —According to ARRS’ American Journal of Roentgenology (AJR), to ensure that patients with emergent or life ...

Time May 18, 2022
arrow
News | Radiopharmaceuticals and Tracers

May 16, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time May 16, 2022
arrow
News | Contrast Media

May 13, 2022 — The ACR Committee on Drugs and Contrast Media, within the ACR Commission on Quality and Safety, is aware ...

Time May 13, 2022
arrow
News | Nuclear Imaging

May 9, 2022 — Novartis announced a temporary, voluntary suspension of production at its radioligand therapy production ...

Time May 09, 2022
arrow
News | Proton Therapy

May 5, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology and the ...

Time May 05, 2022
arrow
News | Coronavirus (COVID-19)

May 4, 2022 — While the COVID-19 pandemic transitions through various phases, nuclear cardiology teams should maintain a ...

Time May 04, 2022
arrow
News | Radiation Therapy

May 4, 2022 — RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT) ...

Time May 04, 2022
arrow
Subscribe Now